Trial Profile
Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs ERY-ASP (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 24 Jun 2018 According to a ERYtech Pharma media release, the company has ceased the development of Eryaspase in Acute Lymphoblastic Leukemia (ALL)including the withdrawal of its European MAA, based on recent feedback from the regulatory agencies in Europe and the United States, which states that, the company would require an additional investment in order to seek regulatory approval of eryaspase for the treatment of ALL.
- 24 Jun 2018 Status changed from recruiting to discontinued, according to a ERYtech Pharma media release.
- 14 May 2018 According to an ERYtech Pharma media release, full results were presented at the annual meeting of the American Association for Cancer Research (AACR).